Boston Scientific (BSX) Net Income towards Common Stockholders (2009 - 2026)

Boston Scientific has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $1.3 billion for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $1.3 billion, up 98.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (up 75.44% YoY), and the FY2025 annual result was $2.9 billion, up 56.4% from the prior year.
• Net Income towards Common Stockholders came in at $1.3 billion for Q1 2026 at Boston Scientific, up from $672.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.3 billion in Q1 2026 to a low of $97.0 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is $495.0 million (2024), against an average of $488.6 million.
• Across the five-year window, Net Income towards Common Stockholders sank 70.34% in 2022 and surged 300.79% in 2023, its largest moves.
• Boston Scientific's Net Income towards Common Stockholders stood at $126.0 million in 2022, then soared by 300.79% to $505.0 million in 2023, then increased by 11.88% to $565.0 million in 2024, then gained by 18.94% to $672.0 million in 2025, then surged by 99.55% to $1.3 billion in 2026.
• The last three Net Income towards Common Stockholders figures came in at $1.3 billion (Q1 2026), $672.0 million (Q4 2025), and $755.0 million (Q3 2025), per Business Quant data.